Double-Punch therapy tested for Tough-to-Treat blood cancer
NCT ID NCT07185477
Summary
This early-phase study is testing a new two-step approach for patients with multiple myeloma that has come back or stopped responding to many standard drugs. First, patients receive an antibody drug (QLS32015) that helps the immune system target cancer cells. This is followed by an infusion of specially engineered immune cells (CAR-T cells) designed to attack the cancer. The main goals are to see if this combination is safe and can shrink the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.